The goal of this clinical trial is to investigate the efficacy, safety and tolerability of Ivonescimab combined with Cadonilimab and chemotherapy in extensive-stage small cell lung cancer patients. And also explore the potential biomarkers for predicting the efficacy of Ivonescimab combined with Cadonilimab for extensive-stage small cell lung cancer.
Written informed consent must be obtained before implementing any trial-related procedures;
Aged 18-80 years;
Expected survival of more than 3 months;
histologically or cytologically confirmed ES-SCLC according to the American Veterans Cancer Association VALG staging system；
Currently participating in interventional clinical research treatment;
Imaging during the screening period showed that the tumor was surrounded by important blood vessels or had obvious necrosis or cavities, and the investigator judged that the entry of the study would cause bleeding risk.
active autoimmune disease requiring systemic treatment within the past 2 years (e.g., with disease-modifying medications, corticosteroids, immunosuppressants). Replacement therapy (e.g., thyroxine, insulin, or physiological corticosteroid replacement for adrenal or pituitary insufficiency) is not considered a systemic treatment.
history of noninfectious pneumonia/interstitial lung disease requiring systemic glucocorticoid treatment or current noninfectious pneumonia.
Single group
Arm 1
DrugIvonescimab combined with Cadonilimab plus EC
second-line group
DrugAK112+AK104+paclitaxel
6-month Progression-Free Survival (PFS) rate
The 6-month Progression-Free Survival (PFS) rate refers to the proportion of patients who are alive and without disease progression six months after starting treatment.
Progression-free Survival
Progression-free survival measures the length of time during and after treatment that a patient lives with the disease without it progressing.
objective response rate
Objective response rate represents the proportion of patients showing a predefined level of tumor shrinkage or disappearance in response to treatment.
Overall Survival
Overall survival measures the length of time from the start of treatment until death from any cause, indicating the effectiveness of the treatment in prolonging patients\' lives.
duration of response
Duration of response refers to the length of time during which a patient\'s tumor remains in remission or shows a positive response to treatment.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
